Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database

by Christopher R. Chapple, Linda Cardozo, Robert Snijder, Emad Siddiqui, Sender Herschorn
Published 2016-12-01

Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS im...

by Marci English, Boyka Stoykova, Christina Slota, Lynda Doward, Emad Siddiqui, Rebecca Crawford, Dana DiBenedetti
Published 2021-04-01

Correction to: Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS sleep disturbance and sleep-related impairment measures for asses...

by Marci English, Boyka Stoykova, Christina Slota, Lynda Doward, Emad Siddiqui, Rebecca Crawford, Dana DiBenedetti
Published 2021-06-01

The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy

by Karl-Erik Andersson, Nurul Choudhury, Jean-Nicolas Cornu, Moses Huang, Cees Korstanje, Emad Siddiqui, Philip Van Kerrebroeck
Published 2018-08-01

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results...

by Jose E. Batista, Heinz Kölbl, Sender Herschorn, Tomasz Rechberger, Javier Cambronero, Michael Halaska, Alex Coppell, Mathilde Kaper, Moses Huang, Emad Siddiqui
Published 2015-08-01

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

by Andrea Tubaro, José E. Batista, Victor W. Nitti, Sender Herschorn, Christopher R. Chapple, Mary Beth Blauwet, Emad Siddiqui, Moses Huang, Matthias Oelke
Published 2017-06-01